Beskrivelse
Krav
Fullmektig i Norge:
Org.nummer: 986406263
- Org.nummer:
- Foretaksnavn:
- Foretaksform:
- Næring:
-
Forretningsadresse:
Fullmektig i EP:
2018.04.16, US 201862658468 P
CHEAL SARAH ET AL: "Comparative efficacy and toxicity of Lu-177-vs Y-90-theranostic anti-HER2/anti-DOTA(metal) pretargeted radioimmunotherapy (anti-HER2 DOT-APRIT) of HER2-expressing breast cancer xenografts with curative intent.", JOURNAL OF NUCLEAR MEDICINE, vol. 58, no. Suppl. 1, 54, 1 May 2017 (2017-05-01), XP002792686, & ANNUAL MEETING OF THE SOCIETY-OF-NUCLEAR-MEDICINE-AND-MOLECULAR- IMAGING (SNMMI); DENVER, CO, USA; JUNE 10 -14, 2017 & Cheal et al.: "Comparative efficacy and toxicity of 177Lu- vs 90Y-theranostic anti-HER2/anti-DOTA(metal) pretargeted radioimmunotherapy (anti-HER2 DOTA-PRIT) of HER2-expressing breast cancer xenografts with curative intent.", J Nucl Med May 1, 2017 vol. 58 no. supplement 1 54 , 1 May 2017 (2017-05-01), Retrieved from the Internet: URL:http://jnm.snmjournals.org/content/58/ supplement_1/54 [retrieved on 2019-07-05] (B1)
CHRISTIAN KLEIN ET AL: "The use of CrossMAb technology for the generation of bi- and multispecific antibodies", MABS, vol. 8, no. 6, 10 June 2016 (2016-06-10), pages 1010-1020, XP055375293, US ISSN: 1942-0862, DOI: 10.1080/19420862.2016.1197457 (B1)
DAMIAN J. GREEN ET AL: "Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers", CANCER RESEARCH, vol. 76, no. 22, 2 September 2016 (2016-09-02), pages 6669-6679, XP055590462, US ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-16-0571 (B1)
YAZAKI PAUL J ET AL: "A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS, vol. 26, no. 3, March 2013 (2013-03), pages 187-193, XP002792685, ISSN: 1741-0134 (B1)
P. J. YAZAKI ET AL: "Humanization of the anti-CEA T84.66 antibody based on crystal structure data", PROTEIN ENGINEERING DESIGN AND SELECTION, vol. 17, no. 5, 1 January 2004 (2004-01-01), pages 481-489, XP055003918, ISSN: 1741-0126, DOI: 10.1093/protein/gzh056 (B1)
WO-A1-2017/194438 (B1)
WO-A2-2016/130539 (B1)
LARSON STEVEN M ET AL: "Radioimmunotherapy of human tumours.", HHS Public Access Author Manuscript , vol. 15, no. 6 June 2015 (2015-06), pages 1-35, XP002792687, DOI: 10.1038/nrc3925 Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/artic les/PMC4798425/pdf/nihms767047.pdf [retrieved on 2019-07-05] (B1)
Statushistorie
Hovedstatus | Beslutningsdato, detaljstatus |
---|---|
EP patent gjort gjeldende i Norge | EP patent besluttet gjeldende i Norge |
EP under behandling | Forespørsel om å gjøre EP patent gyldig er mottatt |
Korrespondanse
Dato
Type korrespondanse
Journal beskrivelse
|
---|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Varsel om betaling av første årsavgift (3319) (PTEP3781200)
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Innkommende
EP Publiseringsdokument fra EPO
|
Utgående
EP Registreringsbrev (3210) (PTEP3781200)
|
Innkommende, AR626541947
Søknadsskjema Patent
|
Innkommende
EP Publiseringsdokument fra EPO
|
Til betaling:
Betalingshistorikk:
Beskrivelse / Fakturanummer | Betalingsdato | Beløp | Betaler | Status |
---|---|---|---|---|
Årsavgift 7. avg. år (EP) expand_more expand_less | 2025.03.21 | 2860,0 | ANAQUA SERVICES | Betalt og godkjent |
Årsavgift 7. avg. år (EP)
2860,0 = 1 X 2860,0
En ordre på saken er opprettet av: ANAQUA ANAQUA (21.03.2025 10:26:56): Betalt |
||||
32409922 expand_more expand_less | 2024.07.30 | 7254 | PLOUGMANN VINGTOFT NUF | Betalt |
Gebyr ved bruk av MasterCard-kort
104 = 104 X 1
Valideringsgebyr EP-patent
7150 = 1 X 7150
|